Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
CONCLUSION: GLP-1 RA therapy represents an important add-on therapy option for achieving decreased insulin doses, weight loss, and modest improvements in HbA1c levels without significantly increasing hypoglycemia risk in patients with T1DM. Patients who have detectable C-peptide and/or are overweight or cannot achieve glycemic goals without hypoglycemia have been found to benefit the most from GLP-1 RA therapy. Further studies are warranted to evaluate these agents' potential impact on clinical outcomes such as microvascular and macrovascular complications.
PMID: 31612934 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - Category: Drugs & Pharmacology Authors: Guyton J, Jeon M, Brooks A Tags: Am J Health Syst Pharm Source Type: research
More News: Byetta | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Gastroenterology | Insulin | Obesity | Study | Victoza | Weight Loss